Market Place
Sourcing Support
Eagle Pharma TiP on Pedia IV Amisulpride PONV Ph2/3 at SAMBA 2024
30 Apr 2024 //
GLOBENEWSWIRE
Eagle: Sustained Amisulpride PONV Response At ASPAN 2024
15 Apr 2024 //
GLOBENEWSWIRE
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride
06 Dec 2023 //
GLOBENEWSWIRE
Sunovion and Otsuka Initiate Phase 3 Development of Non-Racemic Amisulpride
09 Feb 2022 //
BUSINESSWIRE
LB to present Full Results of Dopamine Receptor Occupancy Study of LB-102
07 Dec 2021 //
BUSINESSWIRE
Acacia Pharma’s new cancer care injection approved in Europe
29 Sep 2021 //
PHARMAFILE
Acacia Announces Submission &Validation of MKT Authorization for BARHEMSYS®
29 Sep 2021 //
GLOBENEWSWIRE
BARHEMSYS® (amisulpride injection) Launched in the US for the Treatment
24 Aug 2020 //
GLOBENEWSWIRE
Acacia Pharma`s twice spurned drug finally makes the FDA cut
28 Feb 2020 //
ENDPTS
Acacia, twice foiled by Mfg CRLs, gets 2020 PDUFA after on new API maker
01 Oct 2019 //
FIERCE PHARMA
Acacia eyes February FDA verdict for refiled nausea drug Barhemsys
27 Sep 2019 //
PMLIVE
Second CRL given to Acacia after ‘continuing deficiencies’
09 May 2019 //
IN-PHARMATECHNOLOGIST
Second CRL given to Acacia after ‘continuing deficiencies’
08 May 2019 //
IN-PHARMATECHNOLOGIST
Acacia Pharma Provides Regulatory Update, Receives CRL
15 Oct 2018 //
NASDAQ
Acacia’s PONV drug under US review
08 Jan 2018 //
PHARMA TIMES
Acacia Pharma Announces FDA Acceptance of NDA Filing For BAREMSIS
04 Jan 2018 //
PR NEWSWIRE
Acacia Pharma Announces Positive Results from Second Pivotal
04 Jan 2015 //
PR NEWS WIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.